appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Epigral Ltd
EPIGRAL
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Epigral Limited (formerly Meghmani Finechem Limited) is a manufacturer of essential chemicals, primarily focused on the production of chlor alkali and its derivatives, used across various industries.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Solar Industries India Ltd
Linde India Ltd
Deepak Nitrite Ltd
Castrol India Ltd
Sumitomo Chemical India Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Press Release
Epigral Limited has informed the Exchange regarding a press release dated April 22, 2024, titled "Epigral Limited Q4FY24 PAT rises by 55% to ₹ 77 Cr as against Q3FY24". | Download
Epigral Limited has informed the Exchange regarding a press release dated April 22, 2024, titled "Epigral Limited Q4FY24 PAT rises by 55% to ₹ 77 Cr as against Q3FY24". | Download
Cash Dividend
Final • Div/Share: ₹ 2.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant